Abstract | BACKGROUND: METHODS: RESULTS: A total of 68 studies were included in the meta-analysis. Comparison of DPP-4 inhibitors with placebo in Asian patients showed a decrease in glycosylated hemoglobin (HbA1c ) favoring DPP-4 inhibitors (weighted mean difference [WMD], -0.81%; 95% confidence interval [CI], -0.95% to -0.68%; P < 0.001). Comparison of HbA1c changes between Asian and Caucasian patients showed a significant between-group difference of -0.18% (95% CI, -0.32% to -0.04%; P = 0.011) when compared with placebo. In Asian patients, the homeostatic model assessment for β-cell function (HOMA-β) was increased with DPP-4 inhibitors compared with placebo (WMD, 7.90; 95% CI, 4.29 to 11.51; P < 0.001), although to a lesser extent in Caucasian patients. Comparisons between Asian and Caucasian patients showed a significant between-group difference of -4.97 (95% CI, -9.86 to -0.09; P = 0.046) compared with placebo. Body weight increase with DPP-4 inhibitors compared with placebo was comparable in Asian and Caucasian studies (WMD, 0.37 kg and 0.45 kg and 95% CI, 0.04-0.69 and 0.27-0.62, respectively). CONCLUSIONS:
|
Authors | Xiaoling Cai, Xueyao Han, Yingying Luo, Linong Ji |
Journal | Journal of diabetes
(J Diabetes)
Vol. 7
Issue 3
Pg. 347-59
(May 2015)
ISSN: 1753-0407 [Electronic] Australia |
PMID | 25043156
(Publication Type: Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't)
|
Copyright | © 2014 Ruijin Hospital, Shanghai Jiaotong University School of Medicine and Wiley Publishing Asia Pty Ltd. |
Chemical References |
- Dipeptidyl-Peptidase IV Inhibitors
|
Topics |
- Asian People
(statistics & numerical data)
- Diabetes Mellitus, Type 2
(drug therapy, ethnology)
- Dipeptidyl-Peptidase IV Inhibitors
(therapeutic use)
- Humans
- Insulin-Secreting Cells
(drug effects)
- Treatment Outcome
- White People
(statistics & numerical data)
|